According to Consort Medical, Nicoventures, a subsidiary of the British American Tobacco Group, has awarded a contract to Consort’s Bespak Division “for the supply of an innovative nicotine inhalation product for use as a safer alternative to smoking.” In November 2011, Bespak announced the award of a development contract for scale-up of the “cigarette-like device.” The new nicotine inhaler includes a proprietary valve from Bespak, and the company will manufacture and assemble the product, including the canister.
Consort Medical CEO Jon Glenn said, “This is an exciting contract award for Consort Medical, which further demonstrates the full spectrum of the Group’s competencies, from product development, through to drug handling and full device assembly. The full extent of the revenue opportunity will only become evident following regulatory approval and the product launch. Whilst we do not expect any near term revenue impact, we are optimistic about the prospects for the product in this very promising market.”
Read the Bespak press release.
